WHO Recognizes Egypt as Global Leader in Hepatitis C Elimination
Egypt has become the first country in the world to achieve the gold level certification from the World Health Organization (WHO) in its path toward the elimination of Hepatitis C, marking a historic global health milestone.
This recognition, officially granted in 2023, highlights Egypt's unparalleled national efforts to tackle a disease that has long been a major public health burden.
The achievement was made possible through the ambitious 100 Million Health presidential initiative, one of the largest public health campaigns of its kind, which resulted in over 60 million people being screened for Hepatitis C across the country. More than 4.3 million patients received free treatment, helping reduce liver disease and prevent future complications, including liver cancer.
According to WHO, Egypt now accounts for 70 percent of all Hepatitis C treatments in the Eastern Mediterranean Region and 35 percent of all treatments delivered worldwide. Since 2018, Egypt has managed to reduce hepatitis-related deaths by 35 percent, proving that with strong political will and strategic healthcare policies, eliminating a major disease is achievable.
On World Hepatitis Day, observed annually on July 28, WHO emphasized that Hepatitis remains a serious health challenge in many parts of the world, particularly in the Eastern Mediterranean Region where 27 million people are infected and nearly 97,000 people die each year from preventable hepatitis-related complications.
This year's global theme, 'Simple Steps to Eliminate Hepatitis,' encourages urgent action to expand access to prevention, testing, and treatment. It also calls for removing the social, financial, and systemic barriers—including stigma—that prevent people from receiving care.
In another major breakthrough, Egypt in December 2024 became the first country in the Eastern Mediterranean Region to achieve control status for Hepatitis B, having reduced the virus's prevalence to below 5 percent among children aged 9 and older, while maintaining vaccination rates above 90 percent.
read more
Gold prices rise, 21 Karat at EGP 3685
NATO's Role in Israeli-Palestinian Conflict
US Expresses 'Strong Opposition' to New Turkish Military Operation in Syria
Shoukry Meets Director-General of FAO
Lavrov: confrontation bet. nuclear powers must be avoided
News
Iran Summons French Ambassador over Foreign Minister Remarks
News
Aboul Gheit Condemns Israeli Escalation in West Bank
News
Greek PM: Athens Plays Key Role in Improving Energy Security in Region
News
One Person Injured in Explosion at Ukrainian Embassy in Madrid
News
Israeli-Linked Hadassah Clinic in Moscow Treats Wounded Iranian IRGC Fighters
Arts & Culture
"Jurassic World Rebirth" Gets Streaming Date
News
China Launches Largest Ever Aircraft Carrier
Videos & Features
Tragedy Overshadows MC Alger Championship Celebration: One Fan Dead, 11 Injured After Stadium Fall
Lifestyle
Get to Know 2025 Eid Al Adha Prayer Times in Egypt
Business
Egyptian Pound Undervalued by 30%, Says Goldman Sachs
Arts & Culture
South Korean Actress Kang Seo-ha Dies at 31 after Cancer Battle
Sports
Get to Know 2025 WWE Evolution Results
News
"Tensions Escalate: Iran Probes Allegations of Indian Tech Collaboration with Israeli Intelligence"
Arts & Culture
Hawass Foundation Launches 1st Course to Teach Ancient Egyptian Language
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
See - Sada Elbalad
10 hours ago
- See - Sada Elbalad
Saudi Arabia Approves First Alzheimer's Treatment
Israa Farhan Saudi Arabia has approved its first-ever treatment for Alzheimer's disease, marking a major step forward in the kingdom's efforts to expand cutting-edge healthcare. The Saudi Food and Drug Authority (SFDA) announced on Tuesday the registration of the drug Leqembi (Lecanemab), a pioneering biologic therapy administered via intravenous infusion every two weeks. The medication is designed for patients in the early stages of Alzheimer's, including those with mild cognitive impairment or early dementia. It specifically targets individuals who carry no more than one copy of the ApoE4 gene variant, which is associated with increased Alzheimer's risk. According to the SFDA, Leqembi belongs to a new class of innovative biologic drugs developed using monoclonal antibody technology. The treatment works by targeting beta-amyloid proteins that build up in the brain, helping to slow the formation of plaques known to be linked to cognitive decline in Alzheimer's patients. The approval followed a thorough evaluation of the drug's efficacy, safety, and quality. Clinical trials have shown promising results, indicating that the treatment can slow disease progression compared to a placebo, based on standard clinical measures used to assess Alzheimer's treatments. Common side effects reported include headaches, infusion-related symptoms, and changes detectable by MRI scans known as Amyloid-Related Imaging Abnormalities (ARIA), which may involve brain swelling or microbleeds. These effects are associated with the drug's mechanism and are closely monitored during treatment. The SFDA stressed the importance of regular monitoring throughout the treatment period, especially to track potential side effects. It also highlighted the need for genetic screening before starting the therapy to reduce the risk of adverse reactions. As part of the approval conditions, the pharmaceutical company is required to submit ongoing safety and efficacy reports and implement a robust risk management plan to ensure safe and effective use of the drug. read more Gold prices rise, 21 Karat at EGP 3685 NATO's Role in Israeli-Palestinian Conflict US Expresses 'Strong Opposition' to New Turkish Military Operation in Syria Shoukry Meets Director-General of FAO Lavrov: confrontation bet. nuclear powers must be avoided News Iran Summons French Ambassador over Foreign Minister Remarks News Aboul Gheit Condemns Israeli Escalation in West Bank News Greek PM: Athens Plays Key Role in Improving Energy Security in Region News One Person Injured in Explosion at Ukrainian Embassy in Madrid News Israeli-Linked Hadassah Clinic in Moscow Treats Wounded Iranian IRGC Fighters Arts & Culture "Jurassic World Rebirth" Gets Streaming Date News China Launches Largest Ever Aircraft Carrier News Ayat Khaddoura's Final Video Captures Bombardment of Beit Lahia Videos & Features Tragedy Overshadows MC Alger Championship Celebration: One Fan Dead, 11 Injured After Stadium Fall Business Egyptian Pound Undervalued by 30%, Says Goldman Sachs Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt Arts & Culture South Korean Actress Kang Seo-ha Dies at 31 after Cancer Battle Arts & Culture Lebanese Media: Fayrouz Collapses after Death of Ziad Rahbani Sports Get to Know 2025 WWE Evolution Results
See - Sada Elbalad
a day ago
- See - Sada Elbalad
13 Children Die of Hunger in Darfur IDP Camp
By Ahmad El-Assasy The Sudanese Doctors Network has raised alarm over the deteriorating humanitarian conditions in the Lagawa Internally Displaced Persons (IDP) Camp in East Darfur, reporting the deaths of 13 children due to severe malnutrition in June alone. The camp, located in the city of El Daein, shelters over 7,000 displaced people, the majority of whom are women and children. According to a statement issued by the network, the camp is suffering from acute food shortages, which have led to a rapid increase in wasting and severe malnutrition, particularly among children. The statement added that in addition to hunger, camp residents are facing repeated attacks by armed groups, posing a serious threat to their safety and worsening the already dire humanitarian situation. The Sudanese Doctors Network called on the international community and humanitarian organizations to act immediately to deliver food, medical care, and protection to the displaced population. It specifically urged urgent aid for children and pregnant women, as well as the need to secure the camp from violence and ensure unhindered access for humanitarian aid. The situation in Lagawa Camp highlights the broader crisis unfolding across conflict-ridden regions of Sudan, where mass displacement, violence, and resource shortages continue to claim innocent lives. read more Gold prices rise, 21 Karat at EGP 3685 NATO's Role in Israeli-Palestinian Conflict US Expresses 'Strong Opposition' to New Turkish Military Operation in Syria Shoukry Meets Director-General of FAO Lavrov: confrontation bet. nuclear powers must be avoided News Iran Summons French Ambassador over Foreign Minister Remarks News Aboul Gheit Condemns Israeli Escalation in West Bank News Greek PM: Athens Plays Key Role in Improving Energy Security in Region News One Person Injured in Explosion at Ukrainian Embassy in Madrid News Israeli-Linked Hadassah Clinic in Moscow Treats Wounded Iranian IRGC Fighters Arts & Culture "Jurassic World Rebirth" Gets Streaming Date News China Launches Largest Ever Aircraft Carrier News Ayat Khaddoura's Final Video Captures Bombardment of Beit Lahia Videos & Features Tragedy Overshadows MC Alger Championship Celebration: One Fan Dead, 11 Injured After Stadium Fall Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt Business Egyptian Pound Undervalued by 30%, Says Goldman Sachs Arts & Culture South Korean Actress Kang Seo-ha Dies at 31 after Cancer Battle Sports Get to Know 2025 WWE Evolution Results Arts & Culture Lebanese Media: Fayrouz Collapses after Death of Ziad Rahbani
Al-Ahram Weekly
a day ago
- Al-Ahram Weekly
Liver cancer to double worldwide, most of cases preventable: Study - Health - Life & Style
The number of people with liver cancer will nearly double worldwide by 2050 unless more is done to address preventable causes such as obesity, alcohol consumption and hepatitis, a study warned on July 29. New cases of liver cancer – the sixth most common form of the disease – will rise to 1.52 million a year from 870,000 if current trends continue, according to data from the Global Cancer Observatory published in the Lancet medical journal. It is also the third deadliest of all cancers, with the study predicting that it will take 1.37 million lives by the middle of the century. However, three out of five cases of liver cancer could be prevented, the international team of experts said. The risk factors are drinking alcohol, viral hepatitis and a build-up of fat in the liver linked to obesity called metabolic dysfunction-associated steatotic liver disease, which was previously known as non-alcoholic fatty liver disease. The viruses that cause hepatitis B and C are expected to remain the leading causes of liver cancer in 2050, according to the study, published on World Hepatitis Day. Vaccination at birth is the best way to prevent hepatitis B, but vaccine coverage remains low in poorer countries including in sub-Saharan Africa, the study said. Unless vaccination rates are increased, hepatitis B is expected to kill 17 million people between 2015 and 2030, it added. Alcohol consumption is estimated to cause more than 21 per cent of all cases of liver cancer by 2050, up more than two percentage points from 2022. Cancer due to obesity-linked fat in livers will rise to 11 per cent, also up more than two percentage points, the researchers calculated. The large-scale study, which reviewed the available evidence on the subject, underscored 'the urgent need for global action' on liver cancer, its authors said. The experts called for more public awareness about the preventable danger of liver cancer, particularly by warning people in the United States, Europe and Asia with obesity or diabetes about fatty liver disease. Follow us on: Facebook Instagram Whatsapp Short link:
